Live feed
·
INSIDERFilingvia Quantisnow
Pieris Pharmaceuticals Inc. logo

Director Geraghty James A returned $0 worth of Series F Preferred Stock to the company (1 units at $0.01), closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
PIRS· Pieris Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PIRS (Pieris Pharmaceuticals Inc.) and more on Quantisnow.